Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
Novavax’s (NASDAQ: NVAX) share price is up over 20% premarket on Friday after its Covid-19 vaccine was found to be 96% effective in preventing cases of the original coronavirus strain in late-stage trials, the company said.
Novavax shares are trading at $225.40 premarket after a 20.13% move. Before the company announced it was developing a vaccine in 2020, its shares were trading around the $10 mark.
The trial was conducted in the UK and was also found to be 86% effective in protecting against the more contagious coronavirus variant discovered in England.
Overall its effectiveness was around 90% when combining data from both versions of the virus.
The company also conducted a smaller trial in South Africa, with volunteers exposed to another variant circulating in the country. The vaccine was only approximately 55% effective but prevented severe illness and death.
The company s now expected to submit applications for regulatory authorisation in various countries.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .